Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 14/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466564 | 0.84 | DAGLA (0.41) | DAGLAFAAHCES1ALDH1A1 | |
| SCHEMBL7048614 | 0.84 | DAGLA (0.41) | DAGLAFAAHCES1XDHALDH1A1 | |
| SCHEMBL6468438 | 0.83 | FAAH (0.40) | DAGLAFAAHCES1XDHALDH1A1 | |
| SCHEMBL6465501 | 0.83 | LONP1 (0.43) | DAGLAFAAHCES1CTSGCMA1 | |
| SCHEMBL6462866 | 0.81 | FAAH (0.38) | DAGLAFAAHCES1XDHALDH1A1 | |
| SCHEMBL7046391 | 0.80 | FAAH (0.37) | DAGLAFAAHCES1XDHALDH1A1 | |
| SCHEMBL6062009 | 0.80 | LONP1 (0.42) | DAGLAFAAHCES1CTSGCMA1 | |
| SCHEMBL7043352 | 0.80 | DAGLA (0.39) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL7049521 | 0.79 | CTSS (0.46) | DAGLAFAAHCES1XDHCMA1 | |
| SCHEMBL6062089 | 0.79 | CTSS (0.43) | DAGLAFAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | DAGLA 2304/4885FAAH 479/4885CES1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.